baricitinib alopecia
Selected indexed studies
- Two Phase 3 Trials of Baricitinib for Alopecia Areata. (N Engl J Med, 2022) [PMID:35334197]
- Baricitinib for the Treatment of Alopecia Areata. (Drugs, 2023) [PMID:37195491]
- European expert consensus statement on the systemic treatment of alopecia areata. (J Eur Acad Dermatol Venereol, 2024) [PMID:38169088]
_Worker-drafted node — pending editorial review._
Connections
baricitinib alopecia is a side effect of
Sources
- Baricitinib for the Treatment of Alopecia Areata. (2023) pubmed
- Two Phase 3 Trials of Baricitinib for Alopecia Areata. (2022) pubmed
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). (2023) pubmed
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata. (2025) pubmed
- Baricitinib: A Review in Severe Alopecia Areata. (2023) pubmed
- Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial. (2024) pubmed
- European expert consensus statement on the systemic treatment of alopecia areata. (2024) pubmed
- PMID:40209015 (2023) pubmed
- Baricitinib in Alopecia Areata. (2022) pubmed
- Baricitinib as the first systemic treatment for severe alopecia areata. (2023) pubmed